Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Increased Occurrences Of Parasomnia Symptoms Experienced By Obstructive Sleep Apnea Patients
Patients suffering from obstructive sleep apnea (OSA) have an increased prevalence of parasomnia symptoms compared with the prevalence rates of individual parasomnias, according to a research abstract presented at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
generic viagra online
Lung Cancer Risk May Be Increased By Ovary Removal
Women who have premature menopause because of medical interventions are at an increased risk of developing lung cancer, according to a new study published in the International Journal of Cancer. The startling link was made by epidemiologists from the Universitçİ de Montrçİal, the Research Centre of the Centre Hospitalier de l"Universitçİ de Montrçİal and the INRS - Institut Armand-Frappier.
News of the day
Health Bills Create Tension Over Abortion Coverage
The Associated Press reports: "Health care legislation before Congress would allow a new government-sponsored insurance plan to cover abortions, a decision that would affect millions of women and recast federal policy on the divisive issue. Federal funds for abortions are now restricted to cases involving rape, incest or danger to the health of the mother. Abortion opponents say those restrictions should carry over to any health insurance sold through a new marketplace envisioned under the legislation, an exchange where people would choose private coverage or the public plan. Abortion rights supporters say that would have the effect of denying coverage for abortion to millions of women who now have it through workplace insurance and are expected to join the exchange. Advocates on both sides are preparing for a renewed battle over abortion, which could jeopardize political support for President Barack Obama"s health care initiative aimed at covering nearly 50 million uninsured and restraining medical costs" (Alonso-Zaldivar, 8/5).
Oncology

Avecia Launches Toolkit For Production Of Antibody Fragments

Avecia Biologics has announced it has created a "toolkit" of technologies to meet the production challenges for the next generation of antibody-based therapeutics. The toolkit consists of four elements, bringing together Avecia"s high yield microbial expression system - pAVEway™ - with innovative downstream technologies for purification, refold and PEGylation. Using Avecia"s expertise in these areas, the company offers its clients rapid process development, combined with tested and well understood platforms applicable to a wide range of antibody fragment types and alternative scaffolds. The first element of the "toolkit" is Avecia"s award-winning pAVEway™ technology, comprising innovative vectors, selected host strains and highly optimised production systems, giving rapid and efficient antibody fragment expression and scale up. Purification technology forms the second part of the package, with Avecia"s recent development of two complementary purification technologies for use with antibody fragments produced in microbial systems. The first - a universal platform - offers optimised screening for rapid selection and has been demonstrated on a range of antibody fragments. The second is an affinity platform, and has high selectivity for antibody fragments, even at low concentration. The third element of the "toolkit" is a Refold platform, where Avecia has developed a rapid optimisation procedure for protein refolding. The company"s experience includes the successful use of refolding in the clinical manufacture of over 25 different products. The final part of the offering is PEGylation technology. PEGylation is the method of choice for improving the pharmacokinetic properties and immunogenicity profiles of proteins, including antibody fragments. Avecia has a track record of success with maleimide PEGylyation and is now also collaborating with PolyTherics, a company specialising in precision engineering of protein half-life, to apply its proprietary technologies to antibody fragments. Dr Mark Carver, Chief Scientific Officer at Avecia Biologics, said: "Packaging our capabilities for antibody fragment production together in this way will enable our customers to choose the elements most applicable to the development of their molecule. We are committed to being at the forefront of technologies which will help deliver robust and reliable production processes rapidly to our clients, thereby reducing their time to clinic". Avecia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009